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INTRODUCTION 
Retinal ganglion cells (RGCs) undergo degeneration in many human diseases, 
such as glaucoma, diabetic retinopathy, optic nerve atrophy, some inherited 
diseases (dominant optic atrophy, Leber hereditary optic neuropathy). There is 
no effective treatment for progressive vision loss due to RGC degeneration. 
Polysialylated neural cell adhesion molecule (PSA-NCAM) is expressed abun-
dantly in the retina in close proximity to the RGCs. PSA is attached to NCAM 
by two specific polysialyltransferases, II and IV (ST8SiaII, ST8SiaIV). It is 
thought that PSA-NCAM affects not only adhesive properties between cells, but 
also plays a role in the intracellular signaling, which influences cell survival, 
proliferation, differentiation, migration, axon outgrowth and pathfinding, and 
synaptic plasticity. The functions of PSA-NCAM in the retina in the adult are 
not clearly understood. One of the putative roles of PSA-NCAM in the retina is 
in the maintenance of RGC survival.  
The aims of this study were to investigate in detail (a) the survival of RGCs 
in mice deficient for NCAM and ST8SiaII or ST8SiaIV; (b) the protective roles 
of NCAM/PSA-NCAM during excitotoxic retinal damage induced by kainic 
acid (KA); (c) the protective roles of PSA-NCAM in the mouse model of 
diabetic retinopathy (DR).  
Our study demonstrates that the viability and survival of RGCs is dependent 
on the presence of PSA-NCAM expressed by astroglial and Müller cells. 
Excitotoxic retinal damage or diabetic retinopathy induces a decrease in the 
levels of PSA-NCAM and thereby promotes RGC degeneration. The reduction 
of PSA-NCAM levels in these models is mediated by matrix metalloproteinase-
9 (MMP-9), which induces shedding of the extracellular domain of PSA-
NCAM. Our study demonstrates that PSA-NCAM and MMP-9 might be new 
pharmacological targets to combat retinal degeneration.  
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1. REVIEW OF LITERATURE 
1.1. Cell adhesion molecules 
Cell adhesion molecules (CAMs) are proteins associated with the cell membrane. 
They mediate adhesion of cells to one other or to the components of the extra-
cellular matrix through homo- or heterophilic binding. Cell adhesion is crucial 
for histogenesis, morphogenesis as well as for tissue maintenance and functioning 
in embryogenesis and in adulthood. CAMs are divided into four major super-
families: the immunoglobulin cell adhesion molecules, the cadherins, the inte-
grins and the selectins. Neural cell adhesion molecule (NCAM) belongs to the 
immunoglobulin superfamily of CAMs and was first described as a synaptic 
membrane glycoprotein named D2 by JØrgensen and Bock in 1974 (JØrgenson 
and Bock, 1974). Hirn and colleagues described it as BSP-2 protein (Hirn et al., 
1981). Thiery and collegues identified and described it from the retinal and 
brain tissues as neural cell adhesion molecule (Thiery et al., 1977; Cunningham 
et al., 1987). NCAM appears early in embryogenesis and is continued to be 
expressed in adulthood (Chuong and Edelman, 1984). It was recognized that 
NCAM or its polysialylated form PSA-NCAM induces intracellular signaling 
pathways that influence neural activity, the formation of neuronal connections 
and also neuroprotection (Ditlevsin et al., 2007).  
 
 
1.2. Neural cell adhesion molecule (NCAM) 
1.2.1. Structure of NCAM 
NCAM is a cell-surface glycoprotein. Alternative splicing of messenger RNA 
from a single NCAM1 gene yields three major isoforms of NCAM, named due 
to their molecular weight in kilodaltons (kDa), namely NCAM-180, NCAM-
140 and NCAM-120 (Cunningham et al., 1987; Owens at al., 1987). Two 
largest, NCAM-180 and NCAM-140, are integral membrane polypeptides with 
cytoplasmic domains. NCAM-120 is attached to the cell membrane by a 
glycosylphosphatidylinositol (GPI) anchor (Owens et al., 1987). The extra-
cellular parts of the three main proteins are identical and they include five 
immunoglobulin-like (Ig) domains followed by two fibronectin type III (FNIII) 
modules (Fig. 1). The cytoplasmic domain of NCAM-180 differs from NCAM-
140 by an additional sequence of 261 amino acids (Murray et al., 1986; Owens 
et al., 1987). NCAM can exist in a secreted form due to expression of a stop-
exon located between the 12th and 13th exons, which terminates the cording 
sequence, producing a truncated extracellular part of NCAM (Bock et al., 1987; 
Gower et al., 1988). Variation is also achieved by the expression of a variable 
alternatively spliced exon (VASE), located between the 7th and 8th exons, which 
downregulates neurite outgrowth induced by NCAM (Doherty et al., 1992). 
Expression of the VASE exon increases during development and is thought to 
play a role in promotion of tissue stability.  
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Figure 1. NCAM and PSA-NCAM molecules. (A) Isoforms of NCAM: NCAM-180, 
NCAM-140, NCAM-120. All isoforms consist of five Ig-like domains and two 
fibronectin type III modules. NCAM-180 and NCAM-140 have transmembrane module 
and cytoplasmic domain with different molecular weight. NCAM-120 is attached to the 
cell membrane by glycosylphosphatidylinositol (GPI) anchor. (B) Polysialylated form 
of NCAM, where polysialic acid is attached to NCAM at the fifth Ig-like domain of 
NCAM (Aonurm-Helm et al., 2016). 
 
 
1.2.2. Posttranslational modification of NCAM 
Major posttranslational modification of NCAM with polysialic acid (PSA) 
plays an important role in NCAM function. PSA is a long, linear, negatively 
charged homopolymer of alfa-2,8-linked sialic acid, comprising more than 50 
residues. Three isoforms of NCAM can occur in sialylated form (Rougon et al., 
1982). PSA has an enormous degree of hydration, thus, being polysialylated 
NCAM, occupiers much a higher volume and reduces contacts between cell 
membranes (Hoffman et al., 1982; Johnson et al., 2005). NCAM is the pre-
dominant carrier of PSA in vertebrates (Hoffman et al., 1982). Polysialylation 
significantly modifies the functions of the NCAM protein. PSA content is 
strongly regulated during embryonic and postnatal development and this pro-
cess is protein-specific. A limited number of other proteins, apart from NCAM, 
have been found to be polysialylated in mammals, namely: the alfa subunit of 
the voltage-dependent sodium channels (Zuber et al., 1992), CD36 scavenger 
receptors in human and mouse milk (Yabe et al., 2003), and the polysialyl-
transferases, which autopolysialylate themselves (Close et al., 2003). There are 
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six known polysialylation sites in the NCAM protein. The majority of PSA is 
attached to the fifth and sixth polysialylation sites located on the Ig5 domain of 
NCAM (Nelson et al., 1995). It was also demonstrated that the adjacent Ig4 and 
FNIII1 domains are necessary for NCAM distinction and subsequent polysia-
lylation (Nelson et al., 1997, Close et al., 2003). PSA is attached to NCAM in 
the Golgi complex by two specific polysialyltransferases: ST8SiaII (STX) and 
ST8SiaIV (PST). Both STX and PST are highly expressed during development, 
though STX transcript levels are higher. Soon after birth, STX is decreased 
dramatically; however, PST is declined only moderately (Phillips et al., 1997; 
Bruses et al., 2001). It was shown that STX and PST work cooperatively: the 
addition of PSA at the sixth N-glycosylation site on the Ig5 domain by PST 
facilitates the synthesis of PSA at the fifth N-glycosylation site in the Ig5 by 
STX, and vice versa (Angata et al., 1998). Thus, PST highly prefers the sixth N-
glycosylation site, but STX strongly prefers the fifth. It was further demon-
strated that STX and PST together polysialilate NCAM more effectively, than 
STX or PST alone (Angata et al., 1998). PSA chains synthesized by PST are 
longer than those synthesized by STX.  
 
 
 1.3. Homophilic interactions of NCAM 
It has been shown that NCAMs can attach to each other, an example of homo-
philic binding. Binding between NCAM proteins expressed on the surface of 
one cell membrane is called homophilic cis-interactions. Binding between 
NCAM proteins located on adjacent membrane surfaces is called homophilic 
trans-interactions (Chuong and Edelman, 1984). There are a lot of controversial 
mechanisms in the literature concerning homophilic NCAM binding. NCAMs, 
located on the cell membrane, are arranged in cis-dimeric forms: the first two 
Ig-like modules of one NCAM form parallel cis-bindings with two Ig-repeats of 
another NCAM (Kasper et al., 2000; Soroka et al., 2003). However, in the 
present of adjacent NCAM-expressing cells, cis-dimers are arranged in anti-
parallel manner where bindings occur between the second and third Ig-modules. 
Anti-parallel NCAM-dimers interact in trans- and form the one-dimensional 
“flat zipper” conformation, where the second and third Ig domains of the two 
opposing NCAMs bind two each other, or the one-dimensional “compact 
zipper” conformation, where the first three Ig-like domains of the two adjusting 
NCAMs interact with each other. Combinations of the flat and compact zippers 
form a strong two-dimensional zipper (Soroka et al.,2003; Kiselyov et al., 
2003). Thus, NCAM molecules interact in trans and form the tight two-
dimensional zippers, which leave no space for PSA-moiety and favor adhesion 
between cells. PSA molecules attached to NCAM occupy a large volume and, 
therefore, polysialylated NCAM can only form the weak one-dimensional 
zippers, which favor signaling via heterophilic interactions of PSA-NCAM 
(Kiselyov et al., 2005).   
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1.4. Heterophilic interactions of PSA-NCAM  
1.4.1. Interaction with fibroblast growth factor receptor 1 
(FGFR1) 
It is thought that expression of PSA on NCAM firstly reduces the adhesive pro-
perties of NCAM and secondly that PSA positively regulates interaction with 
other proteins and modulates signaling processes. It has been suggested that 
NCAM/PSA-NCAM can play a role as a receptor, independently of its adhesive 
properties. Using a surface plasmon resonance analysis and nuclear magnetic 
resonance, a direct interaction between FNIII 1 and 2 modules of NCAM and Ig 
modules 2 and 3 of FGFR1 were shown (Kiselov et al., 2003). Interactions with 
FGFR1 take place only when NCAM presents in a polysialylated form. Trans-
homophilic association between PSA-NCAM leads to the formation of one-
dimensional zippers and permits the interactions between NCAM and FGFR1. 
When NCAM is not polysialylated, NCAM forms the two-dimensional tight 
zipper conformation, without space for interaction with other molecules (Kise-
lov, et al., 2005). Thereby, FGFR1 cannot be activated when NCAM is unpoly-
sialylated. Activation of FGFR1 mediated by heterophilic PSA-NCAM binding 
results in dimerization and phosphorylation of FGFR1 that leads to activation of 
phosphatidylinositol 3-kinases (PI3K) and phosphorylation and activation of 
serine/threonine-specific protein kinase (Akt), also known as protein kinase B 
(PKB) (Neiiendam et al., 2004). Akt has a number of downstream effects which 
play a key role in multiple cellular processes, such as apoptosis, cell proli-
feration, differentiation, migration. The Ras-Raf-MEK-MAPK (ERK) pathway 
is also initiated by the activation of FGFR1 (Neiiendam et al., 2004). Mitogen-
activated protein kinases (MAPK) are also known as extracellular signal-
regulated kinases (ERK). MAPK regulate the activities of several transcription 
factors. Indeed, activation of FGFR1 and subsequent activation of PI3K-Akt 
and Ras-MAPK downstream cell signaling pathways resulted in neuronal cell 
survival and neurite outgrowth (Neiiendam et al., 2004).  
 
 
1.4.2. Interaction with tyrosine receptor kinase B (TrkB) receptor 
PSA-NCAM plays a role in brain-derived neurotrophic factor (BDNF) sig-
naling, due to promotion of phosphorylation of the TrkB receptor (Vutskis et 
al., 2001). PSA may delay the diffusion of BDNF away from the cell memb-
rane, thereby facilitating the activation of TrkB (Muller et al., 2000). A direct 
interaction between PSA-NCAM and the TrkB receptor is also possible, leading 
to a clustering and more efficient signaling of the TrkB receptor (Cassens et al., 
2010). TrkB receptor phosphorylation leads to activation of Ras-MAPK and 
PI3K-Akt signaling cascades, which increases neuronal survival (Cheng et al., 
2002; Hetman et al., 1999).  
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1.4.3. Interaction with glial cell line-derived neurotrophic factor 
(GDNF) and glial factor receptor-alpha (GFR-alpha)  
PSA-NCAM can interact with GDNF and with its receptor GFR-alpha leading 
to phosphorylation of receptor tyrosine kinase Ret, and activation of down-
stream cascades including tyrosine specific phosphor-transferase (Fyn), focal 
adhesion kinase (FAK), MAPK, PI3K pathways, eventually increasing cell 
viability (Paratcha, et al., 2003; Jing et al., 1996; Worby et al., 1996). GDNF 
has been demonstrated to be a survival factor for neuronal cells (Linn et al., 
1993; Trupp et al., 1996).  
 
 
1.4.4. NCAM-signaling via non-receptor tyrosine kinase  
NCAM induces phosphorylation of non-receptor tyrosine kinase Fyn and sub-
sequent phosphorylation of another non-receptor tyrosine kinase, FAK (Chatto-
padhyaya et al., 2013). Activated Fyn and FAK trigger downstream cascades, 
which finally activate MAPK and PI3K-Akt that are involved in cell survival, 
migration, division (Carry et al., 1999; Neiiendam et al., 2004). Other pathways 
triggered by FAK and also by activation of FGFR1 involve regulation of 
activity of phospholipase C (PLCy), p53, that influences cell apoptosis (Franke 
et al., 1997; Neiiendam et al., 2004).  
 
 
1.4.5. Interaction with N-methyl-D-aspartate (NMDA) receptor 
It was shown previously that PSA-NCAM interacts with NMDA. NMDA is a 
type of ionotropic glutamate receptor found abundantly in nerve cells. The 
NMDA receptor is assembled as a tetramer, consisting of different combina-
tions of seven subunits: GluN1, GluN2(A-D), GluN3(A-B). Overactivation of 
the receptor induces excessive influx of Ca2+ into the cell and subsequent 
excitotoxicity. It was demonstrated that PSA-NCAM inhibited NMDA recep-
tors in hippocampus and deficits in NCAM/PSA-NCAM increased GluN1 and 
GluN2B-mediated Ca2+ influx in CA1 pyramidal cells in hippocampal slices 
(Kochlamazashvili et al., 2010). PSA prevented the activation of GluN1 and 
GluN2B subunits and decreased glutamate-induced cell death in primary 
hippocampal culture (Hammond et al., 2006).  
 
 
1.5. NCAM/PSA-NCAM expression in the brain 
During embryogenesis and early postnatal development, PSA-NCAM is ex-
pressed throughout the entire nervous system, though its expression gradually 
shifts to the NCAM protein at different rates in different regions of the adult 
nervous system (Rougon et al., 1982; Hoffman et al. 1983; Schlosshauer et al., 
1984; Seki and Arai, 1991; Rutishauser et al., 1996). The relative amount of 
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each of the three isoforms of NCAM varies between different brain regions. All 
three isoforms of NCAM polypeptides have been found in extracts of adult 
forebrain and cerebellum; however, cerebral cortex contains only NCAM-140 
and NCAM-120 (Rougon et al., 1982). Interestingly, PSA-NCAM protein was 
largely found in the adult brain in the regions with ongoing plasticity and neuro-
genesis, such as the hippocampal subgranular zone (SGZ), located in the 
dentate gyrus between the granule cell layer and the hilus, the subventricular 
zone in the walls of the lateral ventricular (SVZ), and the rostral migratory 
stream (RMS) of the olfactory system. PSA-NCAM is expressed by transit 
amplifying cells (D1 cells) in the SGZ, and by committed neuroblasts (D2, D3 
cells in SGZ, and A-cells in SVZ). Neurogenesis in the hippocampus in 
adulthood gives rise to new granule cells in the dentate gyrus, the axons of 
which comprise the mossy fiber tract that connect the dentate gyrus with the 
cornu Ammonis region 3 (CA3), one of the hippocampal subfields. Interneurons 
in the olfactory bulb are generated in the SVZ in the adult and they migrate 
through the RMS to reach their final location (Altman et al., 1969; Luskin et al., 
1993). PSA-NCAM protein is a characteristic feature of neurogenic niches in 
the adult, although PSA-NCAM is not expressed by stem cells nor in SGZ or 
SVZ (Gascon et al., 2010). PSA-NCAM is found also in neurons of piriform 
cortex layer II, which receives olfactory fibers from the olfactory bulb, in the 
cerebral cortex in L cells, in amygdala (Seki and Arai, 1993; Kempermann et 
al., 2015; Job et al., 2015; Varea et all, 2005; Varea et al., 2011). Thereby, PSA-
NCAM expression is maintained in the adult brain mostly in the sites with 
ongoing plasticity (Gascon et al., 2010).  
 
 
1.6. NCAM/PSA-NCAM functions in the brain 
PSA-NCAM regulates cell migration, differentiation, neurite outgrowth, synap-
se formation, neuronal survival during development (Angata et al., 2007, Seki 
and Rutishauser, 1998). Genetic or enzymatic removal of PSA causes divergent 
innervation and ectopic synaptogenesis in hippocampus (Seki and Rutishauser, 
1998). Mice deficient for all isoforms of NCAM demonstrate a significant 
reduction in olfactory bulb size and accumulation of migrating precursors along 
the RMS (Cremer et al., 1994).  
PSA-NCAM guides directed and efficient migration of neuroblasts in neuro-
genic niches, plays a role in axonal growth and fasciculation, synaptic inte-
gration of newborn neurons in the adult (Rousselot et al., 1995; Hu et al., 1996; 
Cremer et al., 1994; Cremer et al., 1997). PSA-NCAM is abruptly down-
regulated soon after newborn neurons reach their final location (Rousselot et al., 
1995). PSA-NCAM supports the survival of newly generated neurons in the 
SVZ and RMS (Gascon et al., 2007) and of neurons in vitro (Vutskis et al., 
2006). PSA-NCAM can also reduce glutamate-induced death of hippocampal 
neurons in vitro (Hammond et al., 2006). Moreover, PSA-NCAM is involved in 
regeneration of neuronal fibers (Muller et al., 1994). 
18 
The hippocampus has been thought a critical zone for learning and memory 
formation. NCAM/PSA-NCAM is required for structural remodeling of 
synaptic connections during long-term memory formation in the synapses of the 
hippocampal mossy fibers (Muller et al., 1996). An increase in NCAM poly-
sialylation in hippocampal dentate granule cells and in neurons of the entorhinal 
cortex was observed as a response to learning tasks (Murphy et al., 1996; 
O’Connell et al., 1997). Removal of PSA with injections into the hippocampus 
of endoneuraminidase-N (Endo-N), an enzyme which cleaves alpha-2,8-linked 
polysialic acid, significantly impaired spatial learning in rats (Becker et al., 
1996). The functions of NCAM are believed to shift from promotion of plastici-
ty during development (PSA-NCAM) to mediating structural stability in adult-
hood (NCAM) (Rutishauser and Landmesser, 1996). However, PSA-NCAM 
remains expressed in regions of ongoing plasticity and neurogenesis in the adult 
brain (rev. by Seki, Arai, 1993). 
 
 
1.7. PSA-NCAM in the retina  
1.7.1. Cellular organization of the retina  
Retinal progenitor cells arise from the anterior portion of the neural tube. They 
give rise to all of the neurons and Müller glia cells in the retina, and are them-
selves distributed in three nuclear layers interconnected by two plexiform layers 
(Fig. 2). Photoreceptors (rods and cones) form the outer (most external) nuclear 
layer (ONL). Photoreceptors convert the entering photons into a chemical 
signal. RGCs constitute the innermost nuclear layer (GCL) and their axons form 
the optic nerve and tract. Cell bodies of bipolar, Müller cells and other neurons 
form the inner nuclear layer (INL), located between the GCL and ONL. Bipolar 
cells transfer the visual signal from the photoreceptors to the retinal ganglion 
cells (RGCs). Astrocyte progenitor cells originate from the neuroepithelium of 
the optic stalk and migrate into the retina through the optic nerve head (Tao et 
al., 2014). Müller cells stretch throughout the entire thickness of the retina and 
arrange in a regular fashion. Astrocytes are confined to the nerve fiber layer 
(NFL) and to the ganglion cell layer (GCL) and their distribution correlates with 
the thickness of the NFL. It has been shown previously that the bodies of the 
RGCs are enveloped by close-fitting sheaths formed by the membrane of 
Müller cells (Stone et al., 1995). The intraretinal part of the RGC axons is also 
surrounded by Müller cells and astrocyte processes (Stone et al., 1995). Each 
Müller cell comprises a core of a column, which is the smallest unit for pro-
cessing of visual information. Every unit includes, in addition to the Müller cell, 
one cone and a variable number of rods, three bipolar cells, and one or two 
ganglion cells. Müller cells support the survival of neurons, remove glutamate 
from the inner retinal layers, play an important role in the regulation of the 
volume of extracellular space, guide the light to the photoreceptors. In 
mammals, retinal gliosis is a nonspecific response of glia, including Müller 
19 
cells, astrocytes, microglial cells, to different pathogenic processes. The up-
regulation of intermediate filament proteins, such as glial fibrillary acidic pro-
tein (GFAP), is a mark of gliosis. Reactive Müller cells and astrocytes protect 
neuronal survival by secreting neurotrophic factors including basic fibroblast 
growth factor (bFGF), ciliary neurotrophic factor (CNTF), GDNF ( Zhu et al., 
2012). On the other hand, reactive gliosis induces retinal damage due to forma-
tion of a glial scar and tractional retinal detachment. Activated glial cells also 
release matrix metalloproteinases (Limb et al., 2002). Interestingly, in non-
mammalian vertebrates, injury-induced Müller cells have been demonstrated to 
be able to dedifferentiate, re-enter to a progenitor state, asymmetrically pro-
liferate and generate new retinal neurons, including RGCs for retinal repair 
(Bernardos et al., 2007).  
 
 
 
 
Figure 2. Schematic drawing of the retina layers by Henry Vandyke Carter (Gray H. 
Anatomy: Descriptive and Surgical. England, 1858).  
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1.7.2. Expression of PSA-NCAM in the retina 
All three isoforms of NCAM are expressed during development and adulthood 
in mammalian retina (Sawaguchi et al., 1999, Bartsch et al., 1989). During 
embryogenesis, NCAM/PSA-NCAM is expressed abundantly in all retinal 
layers, by all cell types, including soma and growth cones of RGC axons and 
their contact sites with endfeet of Müller cells (Silver and Rutishauser, 1984; 
Bartsch, 1989). PSA-NCAM is found also in the environment surrounding 
RGCs and their axons in the optic tract and tectum (Yin et al., 1995). In the 
adult vertebrate retina, NCAM is found primarily in the plexiform layers and 
nerve fiber layer, with less immunoreactivity observed in the inner and outer 
nuclear layers, and no detectable histochemical signal of NCAM in the photo-
receptor layer. (Fliesler et al. 1990). In early postnatal ages, highly sialylated 
NCAM continues to be expressed by neuroblasts, young postmitotic neurons, 
including RGC bodies and axons, and Müller cells and astrocytes (Bartsch et 
al., 1989). Starting from the third postnatal week, highly polysialylated NCAM 
disappears from RGC bodies and processes and continues to be expressed only 
by Müller cells and astrocytes in adulthood, although PSA-NCAM is not 
expressed on the parts of Müller cells, contacting the basal lamina in the outer 
retina. Immunohistochemistry at both the light and electron microscopic levels 
reveals, weakly sialylated NCAM in all cell types in the retina and optic nerve 
in adulthood; however, PSA-NCAM is not expressed in the outer segments of 
photoreceptors (Bartsch et al., 1989). Thus, poorly polysialylated NCAM is 
expressed by RGCs in the mature retina, whereas highly polysialylated NCAM 
is expressed by Müller cells and astrocytes in adulthood and remains in close 
proximity to the RGCs (Bartsch et al., 1989). 
 
  
1.7.3. PSA-NCAM functions in the retina  
During development, PSA-NCAM is involved in RGC axon pathfinding in the 
retina: regulates RGC axonal projection to the visual centers (superior colliculi/ 
optic tectum) and plays an important role in RGC axon fasciculation (Monnier 
et al., 2001; Yin et al., 1995; Thanos et al., 1984; Murphy et al., 2007). NCAM/ 
PSA-NCAM facilitates RGC axonal growth along the endfeet of Müller cells 
(Stier and Schlosshauer et al., 1995; Silver and Rutishauser, 1984). Inhibition of 
NCAM/PSA-NCAM in mammals disrupts RGC growth cones, slow their speed 
down and finally stops them in midretina. PSA-NCAM is also involved in RGC 
survival during development. In vitro, neonatal RGCs express PSA-NCAM, and 
removal of PSA-NCAM by Endo-N induces approximately 42% loss of these 
cultured cells (Murphy et al., 2009). At all developmental stages and in adult-
hood, NCAM is present at contacts between all cell types in the retina; thus, it 
seems that NCAM is important for stabilization (Bartsch et al., 1989). Functions 
of PSA-NCAM in the adult retina however, remains unclear. It has been 
proposed that PSA-NCAM is involved in RGC survival in adulthood. PSA-
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NCAM is highly expressed by adult regenerating RGC axons following axo-
tomy in vitro (Bates et al., 1999). Cleavage of PSA-NCAM in the adult retina in 
vivo induced 25% loss of RGC at 14 days (Murphy et al., 2009). The reduction 
in RGCs density was significantly greater following optic nerve transection in 
retinas where PSA had been removed (Murphy et al., 2009). Optic nerve injury 
upregulates significantly PSA-NCAM levels in the retina and in the contra-
lateral superior colliculus (SC), which is the target tissue for RGC axons. PSA-
NCAM was upregulated mainly on astrocytes in SC; however, some intact RGC 
axons (less than 5%) projecting from the ipsilateral eye did express PSA-
NCAM (Murphy et al., 2007; Murphy et al., 2009). PSA-NCAM was not co-
localized with RGC axons in the uninjured SC. Thus, PSA-NCAM could be 
involved in RGC axonal remodeling after injury. On the other hand, at 28 days 
after aspiration of SC, RGC densities decreased by approximately 15% in the 
contralateral eye of NCAM-/- mice, compared with the ipsilateral eye. In 
contrast, there was no a difference in RGC density after SC damage between 
contralateral and ipsilateral retinas in WT mice. Moreover, the SC of NCAM-/- 
mice expressed significantly higher levels of BDNF compared with WT 
littermates. It seems that in adult NCAM-/- animals, the SC promotes RGC 
survival. (Murphy et al., 2009). It could be that BDNF expression is adaptively 
increased in SC of NCAM-/- mice in order to compensate for the lack of PSA-
NCAM. Therefore, it seems that PSA-NCAM may increase survival of unin-
jured and injured RGCs, although the mechanism underlying PSA-NCAM 
protection of RGCs is unclear. PSA-NCAM signaling through FGFR1, TrkB 
receptor, NMDA receptor, GFR-alpha may play a role in the maintenance of 
RGCs after injury. Previously, significant expression of FGFR1 was found on 
RGCs and Muller cells (Catalani et al., 2009). It was also shown that FGFR1 
and FGFs have an important role in the survival and regeneration of RGCs 
(Blanco et al., 2008). TrkB receptor is expressed on RGCs and intraocular 
injections of BDNF increases survival of RGCs following axotomy (Peinado-
Ramon et al., 1996; Mansour-Robaey et al., 1994; Jelsma et al., 1993). Early 
studies demonstrated that PSA-NCAM interacts with GluN1 and GluN2B 
subunits and decreases glutamate-induced cell death in vitro (Hammond et al., 
2006). GluN2B subunit plays a critical role in RGC degeneration induced by 
glutamate excitotoxicity (Bai et al., 2013). NCAM knockout mice demonstrated 
altered NMDA-induced Ca2+ dynamics in RGCs accompanied by a greater loss 
of RGCs (Murphy et al., 2012). Thus, PSA-NCAM may influence the survival 
of RGCs due the regulatory activity of NMDA receptors on RGCs. PSA-
NCAM/NCAM interact with GDNF and its receptor GFR-alpha. It was shown 
that GDNF promotes survival of RGCs after optic nerve transection (Koeberle, 
1998). GDNF can also increase survival of RGCs via glial cells because GFR-
alpha exists in soluble form (Jing et al., 1996). GDNF-GFR-a-Ret complex may 
diffuse from glial cells via extracellular space and activate a signal transduction 
cascade in RGCs thereby enhancing cell survival. Thus, PSA-NCAM may 
regulate signaling through GDNF/GFR-alpha and affect survival of RGCs. 
However, considering the diverse roles of PSA-NCAM in adult brain, the 
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function of PSA-NCAM in the retina in adult might be wider than only a 
protection of RGCs.  
 
 
1.7.4. The roles of PSA-NCAM in the retinal pathologies 
The roles of PSA-NCAM in RGC survival in different retinal diseases has not 
been extensively studied. Increased levels of PSA-NCAM in astrocytes and 
Müller cells of optic nerve has been observed in mice with experimental glau-
coma (Puranen et al., 2014). Excessive light can induce retinal degeneration 
experimentally and may contribute to the development and progression of 
human age-related degeneration (Grimm et al., 2013; Luke et al., 2016b). PSA 
is upregulated in mouse retina following light damage, and retinal cell death 
occurred earlier after enzymatic removal of PSA from the retina (Luke et al., 
2016a). Optic nerve transection is used as a model of optic nerve traumatic 
damage or atrophy. It was demonstrated that injury of optic nerve in mice 
increases PSA-NCAM levels significantly in retina (Murphy et al., 2007). A 
27% greater reduction in RGC density was observed following optic nerve 
transection in the retinas of mice where PSA was removed by intravitreal in-
jection of Endo-N compared with control. (Murphy et al., 2009). Thus, patho-
logical conditions induce an increase in PSA-NCAM in the retina and optic 
nerve. On the other hand, removal of PSA-NCAM from the retina exacerbates 
degeneration of RGGs. The role of PSA-NCAM in diabetic retinopathy (DR) 
has not been studied thus far.  
 
 
1.8. Summary of the literature review  
NCAM belongs to the immunoglobulin superfamily of CAMs. Polysialylated 
form of NCAM influences several intracellular signaling pathways and is 
involved in the regulation of neuroplasticity, such as neurite outgrowth, synapto-, 
neuritogenesis and neuroprotection in the brain. PSA-NCAM is abundantly 
expressed in retina close to RGCs. The roles of PSA-NCAM in retina remain 
unknown. Previous studies have demonstrated changes in the levels of PSA-
NCAM in retina and optic nerve during several pathological processes ac-
companied by RGC degeneration thus suggesting a protective role of PSA-
NCAM for RGCs. Studying PSA-NCAM formation, interactions and functions 
in retina in physiological and pathological conditions can provide new insights 
into the roles of PSA-NCAM that may have potential for improving and 
restoring vision. Furthermore, knowledge on the roles of PSA-NCAM is 
essential for development of new therapies aimed at increasing RGC survival in 
eye diseases, such as glaucoma, diabetic retinopathy and optic nerve atrophy.  
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2. AIMS OF THE STUDY  
1. To evaluate PSA-NCAM expression in the retina of mice with deficiency in 
ST8SiaII, ST8SiaIV or NCAM genes and after intravitreal administration of 
endoneuraminidase-N (Endo-N), which cleaves PSA chains from NCAM, to 
wild type animals. 
2. To explore the impact of retinal PSA-NCAM in the survival of RGCs in 
transgenic animals lacking ST8SiaII, ST8SiaIV or NCAM genes and 
following intravitreal administration of Endo-N to wild type mice.  
3. To evaluate the roles of PSA-NCAM in RGC degeneration following 
intravitreal administration of kainic acid (KA). 
4. To evaluate the mechanisms underlying the reduction in PSA-NCAM and 
RGC degeneration in KA-induced excitotoxicity, with a focus on metallo-
proteinase-9 (MMP-9).  
5. To explore the protective roles of PSA-NCAM in the survival of RGCs in 
streptozotocin-induced diabetic retinopathy in mice. 
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3. MATERIALS AND METHODS 
3.1. Animals 
Experiments were performed in accordance with the guidelines established in 
the Principles of Laboratory Animal Care (Directive 2010/63/EU). All experi-
ments conformed to regional guidelines on the ethical use of animals. Ethical 
committee license nr. 77 (12.02.2016). NCAM-/- mice and NCAM+/+ mice 
used for experiments were obtained by crossing C57BL6-Ncamtm1Cgn+\-hetero-
zygous mice that were purchased from Jackson Laboratories, USA. The 
generation of ST8SiaII and ST8SiaIV knockout mice has been described 
previously (Eckhardt et al., 2000; Angata et al., 2004). The mouse ST8SiaII and 
ST8SiaIV genes were isolated from a mouse129/SvJ genomic DNA library and 
used to create a targeting vector (Angata et al., 2004, Angata at al., 2007). 
ST8SiaII and ST8SiaIV knockout mice were then back-crossed to C57BL/6J 
background for at least six generations. Male and female F5 generation 
knockout mice (ST8SiaII-/-, ST8SiaIV-/-, NCAM-/-) mice and their wild-type 
littermates were used at age 5–6 months (Lobanovskaya et al., 2015). Diabetes 
was induced in male Swiss Webster mice at 2–2.5 months of age by intra-
peritoneal injection of 90 mg/kg streptozotocin twice (STZ, Sigma-Aldrich, St 
Louis, MO, USA). Mice were euthanized at two months after the onset of dia-
betes (Lobanovskaya et al., 2018). Three-to-four-month-old C57BL/6NTac 
male mice were used for experiments (Lobanovskaya et al., 2019). 
 
 
3.2. Intravitreal injections 
Intravitreal injections were performed using a Hamilton syringe (Agilent Manual 
Syringe, 5; Agilent Technologies, Australia). The needle was inserted through the 
sclera and retina into the vitreous chamber of the eye. Attention was taken to 
prevent lens injury as it may promote survival and regeneration after puncture 
(Pernet Di Polo, 2006). Mice were anesthetized with 1.5–2% isoflurane inhalation 
for intravitreal administrations. Intravitreal injection rises intraocular pressure for 
some period of time that can lead to RGC impairment. In our experiments each 
intravitreal injection was performed in a final volume of 2 μl. Thus, equal rising 
of intraocular pressure was induced in all groups of comparison. The dose of KA 
for intravitreal administration was 5 nmol and 10 nmol. To inhibit MMP-9 
activity, a specific MMP-9 inhibitor (2-(N-Benzyl-4-methoxyphenylsulfon-
amido)-5-((diethylamino)methyl)-N-hydroxy-3-methylbenzamide; Abcam, USA) 
was chosen for intravitreal injections. This compound inhibits MMP-9 in low 
concentrations (IC50=5 nM), whereas its inhibitory activity for MMP-1 and for 
MMP-13 is higher (IC50=113 nM and 1050 nM, respectively). Endo-N, pro-
vided by Professor Rita Gerardin-Schahn, is an enzyme that selectively cleaves 
PSA chains from the extracellular domain of NCAM (Gerardy-Schahn et al., 
1995). The dose of Endo-N for intravitreal administration was selected on the 
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basis of a series of preliminary experiments. The effectiveness of Endo-N to 
remove PSA from NCAM was tested by using both Western blotting and 
immunohistochemistry at 24 hours following enzyme administration. It was 
found that 6.5 U of Endo-N was able to complete remove PSA from NCAM in 
the retina (Lobanovskaya et al., 2015, 2019) and this concentration was used for 
intravitreal injections. Lower doses provided only partial efficacy.  
 
 
3.3. RGC immunostaining and cell density analyses 
Mice were anesthetized deeply with chloral hydrate (300 mg/kg, i/p) and per-
fused transcardially using 0.9% saline and then with 4% paraformaldehyde in 
phosphate buffered saline (PBS, 0.1 M, pH=7.4). Retinas were extracted, post-
fixed for 20 min, and wholemounted on gelatinized slides (Lobanovskaya et al., 
2015). For RGC immunohistochemical staining, goat anti-Brn3a (C-20) anti-
body (1:100, Santa Cruz Biotechnology, Germany) was used. The secondary 
antibody was biotinylated anti-goat (1:200; DAKO, Denmark). Immunore-
activity of Brn3a-positive cells was visualized using the peroxidase method 
(Vectastatin ABC kit and Peroxidase substrate kit DAB, Vector Laboratories, 
USA) (Lobanovskaya et al., 2015). The density of Brn3a-positive cells was 
analyzed using a stereology system comprising an Olympus BX-51 microscope 
and the Visiopharm Integrator System (Version 3.6.5.0, Denmark) (Loba-
novskaya et al., 2015). 
 
 
3.4. Immunoblotting analysis 
Tissue preparation, supernatant resolution and transfer of proteins onto mem-
branes was performed as described previously (Lobanovskaya et al., 2015). 
Membranes were blocked with 0.1% (w/w) Tween-20/TBS containing 0.5% 
(w/w) non-fat dried milk powder or with Odyssey Blocking Buffer (PBS) (LI-
COR Biotechnology, USA). For protein detection, the following primary anti-
bodies were used: mouse anti-PSA-NCAM (1:1000; IgM, clone 2–2B, AbCys, 
France or 1:1000; IgM, clone 2–2B, MAB5324, Millipore, USA), rabbit anti-
ST8SiaII (1:400; Proteintech, USA), rabbit anti-ST8SiaIV (1:250; Thermo 
Scientific, USA), mouse anti-active MMP-9 (4A3) (1:1000; Novus, USA), 
mouse anti-GFAP (1:1000; IgG, clone 2-A-5, Chemicon, UK), rabbit anti-β-
actin (1:5000; Sigma, St. Louis, USA or LI-COR, USA) or mouse anti-β-actin 
(1:5000; Sigma, St. Louis, USA). Membranes were then washed and incubated 
with secondary antibodies: anti-mouse HRP (1:400; Thermo Scientific, USA) or 
anti-rabbit HRP (1:2000; Pierce, USA) followed by incubation with ECL 
detection reagent (Amersham, ECL, UK); biotinylated goat anti-mouse IgM 
(1:2000; Vector Laboratories, Inc. USA) followed by IR Dye 680 LT Strepta-
vidin; goat anti-mouse IR Dye 680 LT, IgM (for PSA-NCAM detection), goat 
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anti-mouse IR Dye 680 LT, goat anti-mouse IR Dye 800 CW, goat anti-rabbit 
IR-Dye 680 LT, goat anti-rabbit IR-Dye 800 CW (1:10000; LI-COR, USA).  
The membranes were analyzed by exposure to autoradiography X-ray film 
(Amersham, hyperfilm, UK) or using the Odyssey CLx Infrared Imaging 
System (USA). Optical densities ratios were then calculated and used for 
analysis (Lobanovskaya et al., 2015; 2018; 2019). 
 
 
3.5. Immunohistochemistry  
Sections for immunohistochemical analyses were prepared as described pre-
viously (Lobanovskaya et al., 2015). Sections were incubated with the fol-
lowing primary antibodies: mouse anti-PSA-NCAM (1:1000; IgM, clone: 2–2B, 
AbCys, France or 1:1000; IgM, clone 2–2B, MAB5324, Millipore, USA), goat 
anti-Brn3a (C-20) (1:100, Santa Cruz Biotechnology, Germany), rabbit anti-
GFAP (1:800; 1mg/ml, MAB 3402, Chemicon, USA), rabbit anti-GFAP 
(1:1000; Dako, Denmark), goat anti-MMP-9 (1:500; Abcam, USA) or mouse 
anti-active MMP-9 (4A3) (1:800; Novus, USA). After washes, sections were 
incubated with an appropriate secondary antibody: DyLight 594 goat anti-
mouse IgG+IgM (H+L) (1:300; Thermo Scientific, USA), Alexa Fluor 488 goat 
anti-rabbit IgG (H+L) (1:300–1:500; Invitrogen Molecular probes, USA), 
Streptavidin, Alexa Fluor 488 conjugate (1:1000; Invitrogen Molecular probes , 
USA), biotinylated anti-mouse (IgM), anti-rabbit, anti-goat (1:200; Vector 
Laboratories, Inc., USA), Alexa Fluor 594 goat anti mouse IgM (1:500; Invitro-
gen Molecular probes, USA).  
Fluorescent signals were detected using a confocal microscope (LSM 510 
Zeiss, Germany) and further analyzed for the co-localization of PSA-NCAM 
signal with Brn3a or GFAP. DP55561-10, 561 nm and Argon/2 458, 477, 488, 
514 nm lasers were used. Immunoreactivities were visualized using a peroxi-
dase method (Vectastatin ABC kit and Peroxidase substrate kit DAB, Vector 
Laboratories, USA) and observed using Olympus BX-51 microscope (Loba-
novskaya et al., 2015; 2018; 2019).  
 
 
3.6. Data analysis 
All data are expressed as mean±SEM. One-way ANOVA, two-way ANOVA or 
two-way ANOVA with repeated measures were used for statistical analysis. 
Post-hoc comparisons were made using Bonferroni or Tukey’s tests. Two group 
comparisons were performed using either Mann-Whitney (non-parametric) or 
Student’s t-test (parametric), where appropriate. A p value of less than 0.05 
(p<0.05) was considered to indicate a statistically significant difference.  
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4. RESULTS  
4.1. PSA-NCAM expression in the retina of mice with 
deficiency in ST8SiaII, ST8SiaIV or NCAM genes and  
after administration of Endo-N  
It was shown previously a significant expression of PSA-NCAM in the retina of 
wild type (WT) mice (Murphy et al., 2009). PSA-NCAM protein have not yet 
been studied it the retinas of knockout ST8SiaII or ST8SiaIV mice. We 
assumed that these transgenic animals might have a lack of PSA-NCAM during 
development or in adulthood, which could influence the viability of RGCs in 
mature mice. Western blot analysis and immunohistochemistry were employed 
to examine the levels and distribution of PSA-NCAM in the retina. Un-
expectedly, western blotting demonstrated that PSA-NCAM is expressed in the 
same degree in the retinas of adult WT and in knockout ST8SiaII-/- or 
ST8SiaIV-/- animals (Fig. 3). These data were in sharp contrast to the PSA-
NCAM expression pattern in ST8SiaIV-/- brain where a substantial reduction of 
PSA-NCAM levels was observed (Fig. 3) (Lobanovskaya et al., 2015).  
 
Figure 3. Western blots demonstrating PSA-NCAM protein levels in the adult retina 
and in the mature brain of WT, ST8SiaII-/-, ST8SiaIV-/- mice (Lobanovskaya et al., 
2015).  
 
 
Immunohistochemistry revealed that the distribution of immunopositive signal 
of PSA-NCAM in the retinal sections of WT, ST8SiaII-/- and ST8SiaIV-/- mice 
was the same (Fig. 4). As predicted, immunohistochemical analysis did not 
detect PSA-NCAM protein in the retinal sections of NCAM-/- knockout mice 
(Lobanovskaya et al., 2015) (Fig.4).  
28 
 
 
Figure 4. Representative microphotographs of PSA-NCAM expression in the retinal 
sections from WT, NCAM-/-, ST8SiaII-/- or ST8SiaIV-/- mice. Magnification x400 
(Lobanovskaya et al., 2015). 
 
 
In all genotypes, PSA-NCAM was expressed predominantly in the inner part of 
the retina, largely concentrated near to RGCs although it was not co-localized 
with RGCs (Fig. 5). Further analysis demonstrated that PSA-NCAM co-
localized with GFAP, in the inner part of the retina, where astrocytes and the 
endfeet of Müller cells are located (Fig. 5) (Lobanovskaya et al., 2015). It 
seems that the major source of PSA-NCAM in the adult retina is astrocytes and 
Müller cells surrounding RGCs.  
 
 
 
 
Figure 5. Confocal images of sections double-labelled for PSA-NCAM (red) and Brn3a 
(green, upper panel), a marker for RGCs, or GFAP (green, bottom panel), a marker for 
astrocytes. Magnification x400 (Lobanovskaya et al., 2015). 
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Thus, as PSA-NCAM levels in the retina of adult ST8SiaIV-/- animals was 
unchanged, we assumed that ST8SiaII compensates for the absence of ST8SiaIV 
in adult transgenic ST8SiaIV-/- mice. To prove this hypothesis, we measured 
the levels of sialyltransferases ST8SiaII and ST8SiaIV in the retinas of trans-
genic mice. Western blotting revealed that both sialyltransferases are expressed 
in the retina of WT mice. However, the level of ST8SiaII protein was much 
higher in ST8SiaIV transgenic mice in comparison with controls. The level of 
ST8SiaIV was not changed in the retinas of ST8SiaII-/- mice (Lobanovskaya et 
al., 2015). Next, we were interested whether newborn (P1) mice with a 
deficiency in ST8SiaII or ST8SiaIV protein had altered levels of PSA-NCAM 
expression in the retina. Western blotting demonstrated high PSA-NCAM 
signal in the retinas of newborn (P1) WT animals, but PSA-NCAM signal was 
barely visible in the retinas of knockout ST8SiaII-/- animals, and approximately 
2-fold lower in the retinas of ST8SiaIV-/- mice compared with WT animals 
(Lobanovskaya et al., 2015). These results were expected, as ST8SiaII is not 
expressed during embryogenesis in ST8SiaII-/- transgenic mice. Apparently, 
sialyltransferases work cooperatively during retina development; however, 
ST8SiaIV has less compensatory ability in newborn (P1) animals. As PSA-
NCAM protein was not reduced in adult transgenic ST8SiaII-/- or ST8SiaIV-/- 
mice, Endo-N was used to eliminate PSA from NCAM in the retina. Endo-N is 
an enzyme that selectively cleavages PSA chains on the NCAM molecule 
(Gerardy-Scahn et al., 1995). Western blotting showed that intravitreal injection 
of Endo-N induced a complete long-lasting reduction in the levels of PSA-
NCAM at 2, 14 and 28 days following administration (Lobanovskaya et al., 
2015).  
 
 
4.2. RGC density in the retina of mice with deficiency in 
ST8SiaII, ST8SiaIV or NCAM genes and after administration 
of Endo-N 
Next, we were interested to know whether constitutive deficiency in NCAM and 
sialyltransferases or Endo-N treatment influenced the survival of RGCs. To 
answer this question, we counted Brn3a-immunopositive cells in wholemounted 
retinas of WT, transgenic ST8SiaII-/-, ST8SiaIV-/- or NCAM-/- mice or Endo-N-
treated mice. Brn3a is a marker for RGCs (Nadal-Nikolas et al., 2009). The 
density of RGCs was significantly lower in ST8SiaII-/- mice compared with their 
WT littermates, whereas density in ST8SiaIV-/- animals was normal. Interesting-
ly, in NCAM-/- mice the density of RGCs was significantly higher compared 
with WT littermates (Table 1). A two-way ANOVA demonstrated a significant 
effect of genotype (F3,63=20.98; p<0.0001) (Lobanovskaya et al., 2015). Thus, the 
significant decrease in PSA during development in ST8SiaII-/- mice may 
influence the survival of RGCs. Previously, in vitro removal of PSA by Endo-N 
was demonstrated increased death of neonatal RGCs (Murphy et al., 2009). The 
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higher density of RGCs in NCAM-/- animals compared with control might be due 
to the ability of NCAM to inhibit the proliferation of progenitor cells (Amoureux 
et al., 2000). In order to examine whether removal of PSA from the adult retina 
by Endo-N administration affects the survival of RGCs at 2 and 14 days 
following Endo-N treatment, we calculated RGC density in wholemounted 
retinas. Endo-N-induced reduction in polysialylated NCAM did not affect the 
viability of RGCs in the mature retina (Table 1) (Lobanovskaya et al., 2015). 
Thus, removal of PSA does not affect the survival of RGCs in uninjured retinas in 
adulthood.   
 
 
Table 1. Effect of intravitreal injection of KA on RGC densities in adult wild-type 
(WT), ST8SiaII-/-, ST8SiaIV-/- or NCAM-/- mice. 
 
Group Cell density, cells/mm
2 % reduction Control KA 
WT 3064 ±73  (13) 
1170 ± 76  
(13) 61 
NCAM -/- 3703 ± 121***  (6) 
1379 ± 51  
(6) 62 
ST8SiaII -/- 2772 ± 47*  (9) 
1009 ± 82  
(9) 63 
ST8SiaIV -/- 2944 ± 97  (9) 
1172 ± 97  
(6) 60 
 
Data are expressed as the mean±SEM. *p<0.05, ***p<0.0001 (two-way ANOVA, 
followed by Bonferroni post-hoc test).  
Abbreviations: KA – kainic acid, RGCs – retinal ganglion cells. 
 
 
 
4.3. A constitutive deficiency in ST8SiaII, ST8SiaIV or  
NCAM genes does not affect KA-induced loss of RGCs  
in the adult retina  
Death of RGCs is a hallmark of different retinal diseases, such as glaucoma, 
retinal and optic nerve ischemia and diabetic retinopathy. Overactivation of 
glutamate receptors is thought to play a key role in RGC damage in these 
diseases (Dreyer et al., 1998; Osborn et al., 1999). Glutamate ionotropic recep-
tors in mammals are divided into three groups: α-amino-3-hydroxy-5-methyl-4-
iso-xazolepropionic acid (AMPA), kainate and NMDA receptors, all of which 
are widely expressed in the retina. (Hampson and Manalo, 1998; Santiago et al., 
2008; Puro et al., 1996). KA is a neurotoxin that induces overactivation of all 
types of glutamate receptors with a predominant action at AMPA/kainate 
receptors. To examine whether deficiency in sialyltransferases or NCAM genes 
influences the survival of RGCs after KA-induced injury, intravitreal injections 
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of 5 nmol KA were performed in WT, ST8SiaII-/-, ST8SiaIV-/- or NCAM-/- 
mice. At 24 h following administration of 5 nmol KA, a reduction in the density 
of RGCs by approximately 60% was observed in all groups of animals. A two-
way ANOVA demonstrated a significant effect of KA (F1,63=1029; p<0.0001) 
(Lobanovskaya et al., 2015). It seems that a constitutive deficiency in sialyl-
transferases or NCAM does not affect the toxicity of KA (Table 1).  
 
 
4.4. Endo-N-induced reduction in PSA-NCAM enhances  
the loss of RGCs after KA-administration in wild type mice 
To assess whether a reduction of PSA-NCAM in retina followed by Endo-N 
treatment affects KA-induced toxicity, we performed intravitreal injections of 
KA on the 2nd and 14th day following Endo-N treatment. We found that in 
Endo-N-treated animals, KA was significantly more toxic on the 14th day (82% 
reduction in RGC density; ***p<0.001) but not on the 2nd day following Endo-N 
exposure compared with control animals (62% reduction in RGC density) (two-
way ANOVA followed by post-hoc Bonferroni tests) (Lobanovskaya et al., 
2015). We can conclude that the enzymatic reduction in PSA by Endo-N 
enhances the toxic effects of KA on RGCs. It seems that PSA-NCAM plays a 
role in the survival of injured RGCs, though the mechanisms by which PSA-
NCAM contributes to the viability of neurons remain unclear.    
 
 
4.5. KA-induced reduction of PSA-NCAM in wild type mice 
Next, we were interested to know whether intravitreal injection of KA itself 
interferes with PSA-NCAM levels in the retina. The experiments demonstrated 
that intravitreal administration of KA (10 nmol) induced a loss of RGCs that 
was accompanied by a decrease in PSA-NCAM (Fig. 8, bottom panel). 
Immunohistochemistry in retinal sections showed a pronounced loss of PSA 
from the inner layers of the retina where RGCs are located (Fig. 8, upper panel). 
GFAP up-regulation was also noted after KA treatment, as a nonspecific 
reaction to the retinal injury (Fig. 6) (Lobanovskaya et al., 2019). 
GFAP is a marker for glial cells including Müller cells and astrocytes in the 
retina. After KA treatment, we observed increased GFAP immunoreactivity in 
the NFL and GCL due to activation of astrocytes or Müller cells. GFAP-
positive immunostaining, following KA injection, appeared also in the IPL, 
INL, OPL, ONL in the soma and along the inner and outer stem process of 
Müller cells (Fig. 6) (Lobanovskaya et al., 2019). Thus, a quick response of the 
retina to the injury manifested in up-regulation of GFAP, which is a protective 
reaction of glial cells, and in the shedding of preexisting PSA-NCAM.  
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Figure 6. Representative microphotographs of GFAP-immunoreactive astroglia and 
Müller cells in retinal sections following intravitreal injection of vehicle (control) or KA 
(10 nmol). Magnification ×200. NFL – Nerve fiber layer; GCL – Ganglion cell layer;  
IPL – Inner plexiform layer; INL – Inner nuclear layer; OPL – Outer plexiform layer; 
ONL – Outer nuclear layer. AC – astrocytes, MC – Müller cells, KA – kainic acid 
(Lobanovskaya et al., 2019). 
 
 
4.6. Mechanisms of the KA-induced reduction of PSA-NCAM 
Our next question was to elucidate the mechanisms by which KA induces the 
loss of PSA-NCAM. Previous studies indicated that matrix metalloproteinases 
(MMPs) are involved in KA-induced RGC apoptosis (Zhang et al., 2004a). Pre-
vious studies from our laboratory showed that MMP-9 induces NCAM/PSA-
NCAM cleavage in neural cell lines (Jaako et al., 2016). Therefore, we pro-
posed that KA administration might upregulate MMP-9, which may then lead to 
the observed reduction of PSA-NCAM. Western blotting revealed greatly 
increased expression of the active form of MMP-9 in the retina after KA 
administration (Fig. 7). Immunohistochemistry in retinal sections demonstrated 
that active MMP-9 protein after KA treatment localized primarily to the inner 
parts of the retina where the majority of PSA-NCAM is expressed (Fig. 7) 
(Lobanovskaya et al., 2015). 
 
 
 
 
Figure 7. Effect of intravitreal KA (10 nmol) administration on active MMP-9 protein 
levels. Left panel: immunohistochemistry of active MMP-9 in retinal sections after 
vehicle (control) or KA administration. Middle panel: western blot of active MMP-9 
protein in lysates from control or KA-treated retinas. Right panel: quantitative analysis 
of the MMP-9 protein. The results are expressed as mean ± SEM. ***p < 0.0001 
(Student’s t-test), n = 6 animals per group (Lobanovskaya et al., 2019). 
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Next, our task was to investigate whether MMP-9 is involved in PSA-NCAM 
shedding in the retina after KA administration. To do that, we selected a speci-
fic inhibitor of MMP-9 (MMP-9i). It was found that simultaneous injection of 
KA and MMP-9i decreased both RGC degeneration and PSA-NCAM loss from 
the retina (Table 2), (Fig. 8). The administration of MMP-9i alone did not affect 
PSA-NCAM levels in the retina (Fig. 8) (Lobanovskaya et al., 2019). 
 
 
 
To clarify whether the protective effect of MMP-9i on RGCs is due to de-
creased shedding of PSA-NCAM, PSA was removed from the retina using 
Endo-N administration. Animals received co-injections of Endo-N, MMP-9i 
and KA. We observed that removal of PSA from the retina decreased the 
 
 
 
 
Figure 8. The effect of MMP-9 inhibitor on KA-induced reduction in PSA-NCAM 
levels. Upper panel: representative microphotographs of immunohistochemistry of 
PSA-NCAM protein in retinal sections after vehicle (control), KA, KA+MMP-9i or 
MMP-9i treatments, respectively (from left to right). Bottom panel (left): western blot 
of PSA-NCAM protein in lysates from vehicle (control), KA, KA + MMP- 9i or MMP-
9i-treated retinas. Bottom panel (right): quantitative analysis of PSA-NCAM protein in 
western blot. Western blotting demonstrated approximately 70% reduction in PSA-
NCAM signal in the retinas treated with KA compared with control. The results are 
expressed as mean ± SEM. ***p < 0.0001 (Tukey’s test). Intravitreal administration of 
KA + MMP-9i induced approximately 30% reduction in PSA-NCAM signal compared 
with control. The results are expressed as mean ± SEM. **p < 0.001 (Tukey’s test), n = 
6 animals per group (Lobanovskaya et al., 2019). 
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protective effect of MMP-9i to the RGCs by approximately 20% (Table 2) 
(Lobanovskaya et al., 2015). As Endo-N itself does not influence the survival of 
RGCs, we concluded that the presence of PSA-NCAM at least partly rescues 
RGCs after KA administration. 
 
 
Table 2. The effects of MMP-9 inhibition and its combination with Endoneuraminidase-N 
(Endo-N) on KA-induced RGC death. The data are expressed as the mean ± SEM.  
***p < 0.0001 (Tukey’s Multiple Comparison Test). In brackets: the number of retinas 
studied.  
 
Group RGC density 
(cell/mm2), 
n=12 
RGC reduction 
in comparison to 
control (%)
Group comparisons 
Control (Vehicle) 2533 (12)   
KA 505,5 (11) *** 80 KA vs Control 
KA+MMP-9i 1327 (12) *** 48 KA +MMP-9i vs KA  
Endo-N+KA+MMP-9i 815 (12) *** 68 Endo-N +KA+MMP-9i 
vs KA+MMP-9i  
 
Abbreviations: KA – kainic acid, RGC – retinal ganglion cell, Endo-N – Endoneura-
minidase-N, MMP-9 – matrix metalloproteinase-9, MMP-9i – matrix metalloproteinase-
9 inhibitor.  
 
 
4.7. Survival of RGCs and alterations in the levels  
of PSA-NCAM in diabetic retinopathy (DR) 
DR is a common complication of diabetes. DR can lead to vision deterioration 
and loss due to retinal neurodegeneration. The influence of diabetes on the 
retina has been studied widely in rodent models (Olivares et al., 2017). 
Streptozotocin (STZ)-mediated induction of diabetes is one of the most 
frequently used chemical models of diabetes in animals (Tonade et al., 2017). 
STZ is toxic to insulin-producing pancreatic beta cells due to its similarity in 
structure to glucose, and it can induce Type 1 diabetes (Aileen, 2012). Our task 
was to explore whether STZ-induced diabetes affected PSA-NCAM levels in 
the retina and whether it was associated with RGC loss. At two months after the 
onset of diabetes, we performed immunohistochemistry for Brn3a (marker of 
RGCs) in wholemounted retinas of control and diabetic animals. A reduction in 
the density of RGCs in diabetic mice of approximately 19% in comparison with 
controls was observed (Lobanovskaya et al., 2018). To assess PSA-NCAM 
protein levels in the diabetic retinas, western blotting was performed. We did 
not find any difference in the total levels of PSA-NCAM protein in the diabetic 
retinas versus control. However, immunohistochemistry detected pronounced 
changes in the distribution of PSA-NCAM in diabetic retinas (Fig. 9). In control 
retinas, PSA-NCAM was primarily expressed in the inner part of the retina, i.e., 
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in the NFL, GCL, with some also present in IPL. In contrast, DR induced a 
strong reduction in PSA-NCAM immunopositive signal (approximately 2.2-
fold) in the NFL and GCL with enhanced PSA-NCAM immunoreactivity in the 
IPL and INL (approximately 1.3-fold) and especially in the OPL and ONL 
(about 2.3-fold), where the processes and soma of Müller cells extend (Fig. 9) 
(Lobanovskaya et al., 2018). 
 
 
 
Western blotting also demonstrated increased levels of GFAP in diabetic retinas 
by (approximately 2.0-fold compared with control retinas). Upregulation of 
GFAP in the retinas of diabetic animals was nonspecific and resembled the 
pattern observed after KA injury. In control retinas, sections double-labelled for 
PSA-NCAM and GFAP demonstrated strong co-localization of these markers in 
NFL and GCL. However, in diabetic retinas, both markers were found abun-
dantly in the OPL and ONL (Fig. 9) (Lobanovskaya et al., 2018). We also found 
increased levels of MMP-9 protein (nearly 1.9-fold) in the NFL and GCL of 
diabetic retinas compared with controls. In IPL, INL, OPL, and ONL of diabetic 
retinas, MMP-9 levels were increased to a much lower extent (Lobanovskaya et 
al., 2018). We propose that MMP-9 may induce PSA-NCAM shedding in the 
retina of diabetic mice and that this reduction could contribute to the observed 
loss of RGCs.  
 
 
 
Figure 9. Confocal images of sections double-labelled for PSA-NCAM (red) and GFAP 
(green) of control (upper panel) and diabetic mice (bottom panel). Magnification x400. 
NFL: Nerve fiber layer; GCL: Ganglion cell layer; IPL: Inner plexiform layer; INL: 
Inner nuclear layer; OPL: Outer plexiform layer; ONL: Outer nuclear layer (Loba-
novskaya et al., 2018). 
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5. DISCUSSION 
5.1. PSA-NCAM expression in the retina of WT, ST8SiaII-/-, 
ST8SiaIV-/-, NCAM-/- mice 
The present study demonstrates pronounced expression of PSA-NCAM in the 
retinas of WT animals with predominant localization of the protein in the NFL, 
GCL, IPL. In the other layers of the retina, minimal PSA-NCAM signal was 
found. Co-localization of PSA-NCAM with GFAP marker revealed that only 
Müller cells and astrocytes express PSA-NCAM (Lobanovskaya et al., 2015). 
Our results are consistent with previous studies that demonstrated pronounced 
expression of PSA-NCAM in the mammalian adult retina, primarily by Müller 
and astroglial cells (Bartsch et al., 1989; Murphy et al., 2009). In contrast, 
RGCs do not express PSA-NCAM or at least the level of expression is too low 
to be revealed by the methods employed in this study (Lobanovskaya et al., 
2015). Interestingly, it was shown earlier, using immunohistochemistry at the 
light and electron microscopic levels, that slightly sialylated NCAM is 
expressed by all cell types in the retina and optic nerve in adulthood with the 
exception of the outer segments of photoreceptor cells (Bartsch et al., 1989). 
However, PSA-NCAM is certainly localized closely to RGCs, as observed in 
the double-labelled images for PSA-NCAM and Brn3a. Moreover, it was 
previously found that the membrane of Müller cells and astrocytes is in close 
apposition to the soma and processes of RGCs (Stone et al., 1995). Next, we 
explored the protective role of PSA-NCAM for RGCs in adulthood. We used 
transgenic mice with a constitutive deficiency in ST8SiaII, ST8SiaIV or NCAM 
genes. As sialyltransferase II is predominant during embryogenesis and sialyl-
transferase IV functions primarily in adulthood, we assumed a reduction in 
retinal PSA-NCAM in ST8SiaII-/- or ST8SiaIV-/- transgenic animals in the 
corresponding periods of life. Surprisingly, our data showed that the levels and 
distribution pattern of PSA-NCAM in adult retina was not affected by a 
deficiency of either ST8SiaII or ST8SiaIV. These data contrasted data from 
brain tissue of ST8SiaIV-/- mice, where a remarkable reduction in PSA-NCAM 
levels was observed (Lobanovskaya et al., 2015). Knockout ST8SiaIV animals 
showed a strong reduction in PSA levels in most brain regions: olfactory bulb, 
hippocampus, neocortex, hypothalamus, medulla oblongata in comparison with 
WT at 5–6 weeks of age. However, ST8SiaIV-/- mice did not show any obvious 
changes in brain (Eckhart et al, 2000). However, it was demonstrated that sialyl-
transferase IV is important for synaptic plasticity in hippocampal CA1 synapses 
and cognitive performance (Eckhardt et al., 2000; Angata et al., 1998). In 
ST8SiaII -/- mice, a reduction in PSA levels in hippocampus, olfactory bulb and 
cerebral cortex was also observed, which resulted in defasciculation of mossy 
fibers and altered synaptogenesis in the hippocampus (Angata et al., 1998). In 
contrast to adult retinas, PSA-NCAM immunological signal in the retinas of 
ST8SiaII-/- newborn (P1) mice was virtually absent, and in ST8SiaIV-/- mice 
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PSA-NCAM levels were 2-fold two lower than controls. These data clearly 
demonstrate that a deficiency in ST8SiaII or ST8SiaIV can be fully com-
pensated for during retinal maturation. Previous studies revealed that in the 
brain of newborn (P1) ST8SiaII-/- animals, 45% of NCAM was non-poly-
sialylated; however, in ST8SiaIV-/- mice, only 6% of NCAM was without PSA 
(Galushka et al., 2006). In the same study, ST8SiaII and ST8SiaIV mRNA 
levels were similar to control. Thus, ST8SiaII is more powerful when compen-
sating for NCAM polysialylation in the brain of newborn (P1) ST8SiaIV-/- 
animals due to its higher kinetic properties (Galushka et al., 2006). Thus, these 
previous data are in a line with our results and demonstrate that the com-
pensatory ability of ST8SiaII is higher in the retina of newborn (P1) mice. It has 
been suggested that ST8SiaII and ST8SiaIV mice have different involvement in 
PSA formation and the control of neurological functions with some overlap. As 
expected, animals deficient for the NCAM gene did not show any PSA-NCAM-
related signal in the retina (Lobanovskaya et al., 2015).   
 
 
5.2. RGC density in mice with a deficiency in ST8SiaII, 
ST8SiaIV or NCAM genes and after administration of Endo-N 
Our next experiments demonstrated that constitutive deficiency in the ST8SiaII 
gene results in decreased RGC density in adult mice compared with control, 
whereas in ST8SiaIV-/- mice, the density of RGCs remained unchanged 
(Lobanovskaya et al., 2015). A decrease in PSA-NCAM during development 
and the early postnatal period in ST8SiaII knockout mice may influence the 
survival of RGCs. Recent studies demonstrated an increase in neonatal RGC 
death in vitro after enzymatic removal of PSA by neuraminidase (Murphy et al., 
2009). Furthermore, the viability of RGCs is dependent upon the presence of 
trophic factors produced by their targets – tectal neurons – upon the establish-
ment of their synaptic contacts (Vecino et al., 2004). It seems that PSA-NCAM 
ensures the proper formation of these synaptic contacts during development 
(Yin et al., 1995). Remarkably, in NCAM-/- mice, the density of RGCs was 
statistically increased compared with control (Lobanovskaya et al., 2015). 
These data are consistent with previous work (Murphy et al., 2007). It seems 
that NCAM, in unpolysialylated form, may influence the balance between 
neural progenitor cell proliferation and differentiation. Previous studies demon-
strated that NCAM inhibited proliferation and stimulated neural differentiation 
of neonatal hippocampal and cerebellar progenitor cells (Amoureux et al., 
2000). Thus, a deficiency in NCAM results in an increased production of pro-
genitors without significant alteration to their survival. Previously, NCAM-/- 
mice were shown to have higher levels of BDNF in the superior colliculi (SC) 
(Murphy et al., 2007). It may be proposed that the survival of RGCs in adult 
NCAM-/- mice is increased due to enhanced or prolonged influences of trophic 
factors produced in SC (Murphy et al., 2007). To further clarify the roles of 
PSA-NCAM in the survival of RGCs, we enzymatically reduced PSA in the 
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retina using Endo-N. Intravitreal injection of Endo-N enzyme resulted in 
complete cleavage of PSA chains from the NCAM molecule at the 2nd, 14th and 
28th postinjection days. Our results demonstrated that temporary reduction of 
PSA induced by Endo-N does not affect the survival of RGCs (Lobanovskaya et 
al., 2015). Our data are in contrast with previous studies where a reduction in 
the densities of RGCs was observed following PSA elimination by Endo-N 
(Murphy et al., 2009). The survival of RGCs may depend upon the age of 
animals also. We used animals at 5–6 months of age, whereas previously, 2–3 – 
month-old animals were used (Murphy et al., 2009).  
 
 
5.3. Endo-N-induced reduction in PSA-NCAM enhances the 
loss of RGCs after KA-administration in the adult retina 
The toxic effect of KA on the RGC viability was not changed in mice with 
constitutive deficiency in ST8SiaII, ST8SiaIV or NCAM genes. In contrast, 
enzymatic cleavage of PSA-NCAM in WT mice by Endo-N following 
intravitreal injection of KA at 14th day, but not at 2nd decreases survival of 
RGCs compared with control mice (Lobanovskaya et al., 2015). These data are 
in a line with previous studies showing that the loss in RGCs induced by optic 
nerve transection was higher in retinas that had been pretreated with Endo-N 
(Murphy et al., 2009). The mechanisms underlying the prosurvival effect of 
PSA-NCAM remain to be elucidated. It is not clear why the adult retina is more 
sensitive to the toxic effect of KA after reducing PSA levels. It was demon-
strated previously that PSA-NCAM is able to interact with FGFR1, TrkB 
receptor, and GFR-alpha to trigger downstream cascades affecting the viability 
of RGCs (Blanco et al., 2008; Koeberle, 1998; Peinado-Ramon et al., 1996; ). It 
was also shown that PSA-NCAM promotes survival of RGCs due to its 
modulatory effect on the NMDA receptor and p75NTR (Luke et al., 2016a; 
Murphy et al., 2012).  
 
 
5.4. Mechanism of KA-induced reduction of PSA-NCAM and 
RGC degeneration 
Our experiments demonstrated a remarkable reduction in PSA-NCAM levels at 
24 hours after intravitreal KA in the inner part of the retina (NFL, GCL) 
(Lobanovskaya et al., 2019). The role of PSA-NCAM in RGC survival in this 
model of KA-induced excitotoxicity has not been studied thus far. Previous 
studies suggested that MMPs are involved in NCAM/PSA-NCAM cleavage in 
neurons (Hübsmann et al., 2005; Hinkle et al., 2006; Shichi et al., 2011; Brenn-
mann et al., 2014). It was observed in our laboratory that MMP-9 is the major 
metalloproteinase inducing NCAM/PSA-NCAM cleavage in neuroblastoma 
cells (Jaako et al., 2016). Earlier studies also demonstrated that KA-induced 
excitotoxicity in the retina stimulated upregulation of MMP-9 (Zhang et al., 
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2004a). Our results showed that the active form of MMP-9 was virtually absent 
in the retinas of control animals. In contrast, substantial levels of active MMP-9 
were detected after KA treatment in the NFL and GCL, where PSA-NCAM is 
primarily expressed (Lobanovskaya et al., 2019). We assumed that MMP-9 was 
involved in retinal PSA-NCAM shedding after KA injections. Our next 
experiments revealed that a specific inhibitor of MMP-9, injected in the same 
time as KA, reduced PSA-NCAM cleavage, significantly, in the inner part of 
the retina. Moreover, the survival of RGCs in the KA+MMP-9 inhibitor group 
was also significantly increased compared with the KA alone group. Further 
experiments demonstrated that the removal of PSA from the retina by Endo-N 
partly decreases the protective effect of MMP-9 inhibitor on RGC survival after 
KA-induced excitotoxicity (Lobanovskaya et al., 2019). These results concur 
with previous data demonstrating that KA-mediated upregulation of MMP-9 
increases RGC death partly due to degradation of laminin in the retina (Zhang 
et al., 2004a). Here we revealed that upregulation of KA-induced MMP-9 
results in PSA-NCAM shedding and RGC degeneration. Inactivation of MMP-9 
partly rescued RGC number, due to decreased PSA-NCAM cleavage (Loba-
novskaya et al., 2019). MMP-9 levels are increased in the retina in various 
diseases, such as diabetic retinopathy, age-related macular degeneration, glau-
coma (Kowluru et al., 2010; Kowluru et al., 2014; Singh and Tyagi, 2017). It 
was suggested that MMP-9 is one of the important factors in the progression of 
proliferative diabetic retinopathy (Kosano et al., 1999). MMPs belong to the 
family of zinc-dependent proteases. They have the capacity to degrade and 
remodel the extracellular matrix and affect a wide spectrum of substrates: cell 
surface receptors, proteinases, and signaling molecules (Birkedal-Hansen et al., 
1993). Notably, MMP-9 inhibition only partially decreased PSA-NCAM 
shedding and RGC degeneration. Thus, MMP-9-independent mechanisms are 
also activated to promote PSA-NCAM cleavage and RGC death. The ADAMs 
family of metalloproteinases may be involved in NCAM/PSA-NCAM cleavage 
in the retina (Kalus et al., 2006). For example, it has been shown that plasmin 
can degrade PSA-NCAM and exacerbate RGC degeneration (Endo et al., 1998; 
Mali et al., 2005).   
 
 
5.5. Survival of RGCs and alterations in the levels  
of PSA-NCAM in diabetic retinopathy (DR) 
Considering that DR is a severe complication of diabetes and a leading cause of 
blindness in working-age adults in developed countries, it is critical to study the 
roles of PSA-NCAM in DR and its association with RGC survival. Here, we 
demonstrated a redistribution of PSA-NCAM in the retina of mice during the 
development of STZ-induced DR. In diabetic retinas, PSA-NCAM was 
markedly reduced in the NFL, GCL and was greatly increased in the OPL and 
ONL compared with control retinas (Lobanovskaya et al., 2019). The reduction 
in PSA-NCAM levels in the inner part of the retina was associated with RGC 
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degeneration in diabetic animals. Our study also demonstrated increased levels 
of MMP-9 primarily in the NFL and GCL. MMP-9 was slightly increased in the 
other layers of the retina (Lobanovskaya et al., 2019). We propose that a 
significant upregulation of MMP-9 expression may be involved in PSA-NCAM 
shedding in the inner part of diabetic retina, which exacerbated RGC neuro-
degeneration. MMP-9 is elevated due to retinal inflammation during DR. It has 
been shown that MMP-9 is involved in angiogenesis, that it promotes 
degradation of extracellular matrix and the break-down of the blood-retinal 
barrier (Kowluru et al., 2012). We also observed that DR leads to activation of 
retinal glial cells (Lobanovskaya et al., 2019). It seems that PSA-NCAM is 
expressed on the membrane of Müller cells and astrocytes in the inner and 
middle part of diabetic retinas. Activated Müller cells and astrocytes are the 
source of the MMP-9 in the retina (Limb, 2002; Zhang, 2004b). Moreover, 
gliosis induces the formation of a glial scar and tractional detachment of the 
retina. It was demonstrated previously that NCAM inhibited astrocyte prolife-
ration in vitro and in vivo after damage (Krushel et al., 1995, 1998). It may be 
that reduced glial cell proliferation in the retina helps to create an environment 
more suited to neuronal survival. Thus, on the one hand, PSA-NCAM increases 
survival of RGCs after injury, but on the other, reduction of PSA from the 
middle part of the retina may reduce glial activity and the severity of DR. The 
influence of PSA-NCAM on glial cell proliferation in the retina has not yet 
been studied.  
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CONCLUSIONS  
1. PSA-NCAM is expressed in the same high levels and distributed similarly in 
the retinas of adult WT, ST8SiaII-/-, ST8SiaIV-/- knockout mice. We pro-
pose that sialyltransferases in the retina of transgenic mice are able to 
compensate for each other effectively.  
2. Knockout ST8SiaII-/- mice have decreased density of RGCs compared with 
controls. In contrast, NCAM-/- mice demonstrate an increase in RGC 
density. Thus, the substantially lower levels of PSA during embryogenesis in 
newborn ST8SiaII-/- mice influence the survival of RGCs. Intravitreal 
administration of Endo-N to wild type mice does not influence the survival 
of RGCs.                
3. A constitutive deficiency in ST8SiaII, ST8SiaIV or NCAM genes does not 
affect the toxic effects of KA on RGCs, which may be partly explained by 
the compensatory activation of the existing sialyltransferase. In contrast, 
Endo-N-induced reduction of PSA-NCAM in wild type mice increases 
toxicity of KA to RGCs suggesting that survival of RGCs is dependent upon 
the presence of PSA-NCAM. 
4. KA-induced reduction in PSA-NCAM is mediated by the upregulation of 
MMP-9, which causes shedding of PSA-NCAM and thereby reduces the 
viability of RGCs.  
5. Diabetic retinopathy is associated with a decrease in RGC density and a 
marked reduction in PSA-NCAM protein in the inner part of the retina, 
where RGCs are located. This is accompanied by greatly increased levels of 
MMP-9, in the same region part of the retina close to RGCs. We propose 
that MMP-9 is associated with PSA-NCAM shedding and RGC degene-
ration during diabetic retinopathy. 
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SUMMARY IN ESTONIAN 
Polüsialüülitud närviraku adhesioonimolekuli (PSA-NCAMi) roll 
silma võrkkesta ganglionirakkude elulemusele täiskasvanueas 
Närviraku adhesioonimolekul (NCAM) on glükoproteiin, mis kuulub immuno-
globuliinide superperekonda. Kolm peamist NCAMi isovormi on jaotatud 
molekulmassi alusel (NCAM-180, NCAM-140, NCAM-120) ning need erinevad 
üksteisest rakumembraani läbiva domeeni poolest. Närviraku adhesiooni-
molekulide peamine roll on närvirakkude vaheliste kontaktide loomine ja nende 
stabiliseerimine. Polüsiaalhappe (PSA) seondumine NCAMi viienda immuno-
globuliini domeeni külge toimub polüsialüültransferaas II (ST8SiaII) ja IV 
(ST8SiaIV) vahendusel, ning selle tulemusena väheneb rakkudevaheline adhe-
sioon. Lisaks on näidatud, et PSA-NCAM ei mõjuta mitte üksnes rakkude-
vahelisi adhesiivseid omandusi, vaid sellel on oluline roll ka protsessides, mille 
kaudu reguleeritakse rakkude elulemust, proliferatsiooni, diferentseerumist, 
migratsiooni, aksonite väljakasvu ning sünaptilist plastilisust. PSA-NCAMi 
leidub valdavalt kesknärvisüsteemi neuronitel ning gliiarakkudel ja olles närvi-
rakkudevahelise struktuurse dünaamilisuse vahendaja, omab ta olulist rolli aju 
plastilisuse regulatsioonis nii arenevas ajukoes kui ka täiskasvanueas. Silma 
võrkkestas esineb PSA-NCAMi täiskasvanueas kõige rohkem Mülleri rakkudel 
ja astrotsüütidel ganglionirakkude (RGC) juures. Silma võrkkest koosneb mit-
metest erineva funktsiooniga rakukihtidest, millest ühe kihi moodustavad 
ganglionirakud. Selles kihis paiknevad RGCde kehad, mille aksonid moodus-
tavad nägemisnärvi. On näidatud, et silma võrkkesta PSA-NCAM võib mõju-
tada RGC elulemust, kuid milline on PSA-NCAMi täpne roll täiskasvanueas 
silma võrkkesta funktsiooni tagamisel, pole teada. 
 
Töö eesmärgid: 
1. Tuvastada, kas NCAM, ST8SiaII, ST8SiaIV puudulikel hiirtel ja endosiali-
daas-N-i (Endo-N) indutseeritud PSA defitsiit metsiktüüpi hiirtel esinevad 
muutused PSA-NCAMi ekspressionis ja silma võrkkesta RGCde arvus.  
2. Selgitada, kas ja kuidas mõjutab NCAM-/-, ST8SiaII-/-, ST8SiaIV-/- või 
Endo-N-iga tekitatud PSA kadu silma võrkkesta RGCde elulemust neuro-
toksiini kaiinhappe intravitreaalse manustamise järgselt. 
3. Selgitada, millise mehhanismi vahendusel väheneb PSA-NCAMi tase ning 
tekib RGCde degeneratsioon kaiinhappe intravitreaalse manustamise järg-
selt. 
4. Teha kindlaks PSA-NCAMi ja maatriksi metalloproteinaas-9 (MMP-9) roll 
RGCde elulemusele hiire streptosototsiiniga indutseeritud diabeedi mudelis. 
 
Töö tulemused: 
1. Antud töö tulemused näitasid, et vastsündinud ST8SiaII-/- ja ST8SiaIV-/- 
hiirtel on PSA-NCAMi ekspressioon oluliselt vähenenud, kuid täiskasvanud 
hiirtel ekspressioonis muutusi ei täheldatud. NCAM-/- hiirtel PSA-NCAMi 
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ei leitud. Tuvastati, et NCAM-/- hiirtel on RGCde arv oluliselt suurenenud, 
vastupidiselt ST8SiaII-/- hiirtele, kellel RGCde arv on vähenenud, kuid 
ST8SiaIV-/- hiirtel RGCde arvus muutusi ei esinenud. Samuti selgus, et PSA 
eemaldamine NCAMilt Endo-N-iga ei mõjutanud RGCde elulemust. 
2. Ilmnes, et ST8SiaII-, ST8SiaIV- või NCAM-defitsiitsetel loomadel ei mõju-
tanud kaiinhappe poolt põhjustatud toksilisus RGCde elulemust, mille põh-
juseks võib olla olemasolevate sialüültransferaaside aktivatsioon. Samas, 
Endo-N-iga tekitatud PSA kadu suurendas kaiinhappe toksilist toimet 
RGCdele, mis viitab, et polüsialüülitud NCAMi vorm on vajalik RGCde 
elulemuse tagamiseks. 
3. Selgus, et MMP-9 osaleb kaiinhappest indutseeritud PSA-NCAMi taseme 
vähenemises, põhjustades PSA eemaldamist NCAMilt ning selle mehha-
nismi kaudu mõjutatakseb RGCde elulemust. 
4. Tuvastati, et streptosototsiiniga indutseeritud diabeedi mudelis on RGCde 
arv vähenenud ja see on seotud PSA-NCAMi taseme vähenemisega ning 
MMP-9 aktivatsiooni suurenemisega RGCde piirkonnas. 
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